Lexaria Bioscience has entered into a Material Transfer Agreement with a pharmaceutical company to evaluate Lexaria’s DehydraTECH technology in a pre-clinical setting. Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work should be complete within roughly 6 months or less.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Advances Drug Tolerability in Latest Study
- Lexaria Bioscience says second GLP-1 human pilot study shows zero adverse events
- Lexaria’s Study Suggests Improved Drug Absorption With Food
- Lexaria Bioscience announces first results from second GLP-1 human pilot study
- Lexaria’s Innovative Formulation Leads in Weight Loss Study